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Abstract
Background: Pulmonary hypertension (PH) is a heterogeneous, debilitating condition with highly
relevant impact on functional capacity, quality of life, and life-expectancy.
Objectives: This study aims to provide long-term data on the Portuguese PH population, by
characterising the clinical presentation, evolution, and outcomes of PH patients in a specialised
referral centre.
Methods: Retrospective analysis of a cohort of 101 patients with pre-capillary PH (pcPH) refer-
enced to an expert tertiary care referral centre in northern Portugal from 2002 to 2013.
Diagnosis was confirmed by right heart catheterisation (RHC). PH classification followed consen-
sus criteria from the 5th World Symposium in Nice, 2013.
Results: The most frequent causes of pcPH were Group 1 PH -- pulmonary arterial hyperten-
sion (PAH) (54.4%) and Group 4 PH -- Chronic thromboembolic pulmonary hypertension (CTEPH)
(25.7%); importantly, 17.8% of patients presented PH associated with multiple aetiologies. Tar-
geted therapy was used in 91.1% of patients (48.5% combination therapy). 1-, 3-, and 5-year
survival was estimated at 86.6%, 76.7%, and 64.1%, respectively. Survival was significantly bet-
ter for those ≤40 years old (10.5 vs. 6.4 years; P = 0.003) and for women with I/HPAH (9.3 vs.
4.5 years; P = 0.039).∗ Corresponding author at: Pulmonary Vascular Disease Unit, Centro Hospitalar do Porto -- Hospital de Santo, António, 4099-001 Porto,
Portugal.
E-mail address: reisabilio@gmail.com (A. Reis).
https://doi.org/10.1016/j.pulmoe.2018.02.003
2531-0437/© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusions: This study provides long-term, real-world data for the management of PAH and
CTEPH in Portugal and demonstrates the importance of dedicated electronic medical records
and well defined clinical management protocols for better patient outcomes. Patients pre-
sented mostly with intermediate or high risk of mortality, which suggests delayed diagnosis and
highlights the need to increase awareness among clinicians.
© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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study, clinical classification of PH followed standard criteriantroduction
ulmonary hypertension (PH) is an heterogeneous condi-
ion associated with various underlying disorders, which
s defined as at rest mean pulmonary arterial pressure
mPAP) ≥25 mmHg confirmed by right heart catheterisa-
ion (RHC).1 The pathophysiological processes associated
ith the development of PH are complex and more than
ikely multifactorial, why explains why several types of clas-
ification have been proposed over the years. The most
ecent international consensus from the 5th World Sym-
osium held in Nice in 2013, classifies PH according to
ve general groups of aetiologies.2 Group 1 PH refers to
ulmonary arterial hypertension (PAH) and includes idio-
athic pulmonary arterial hypertension (IPAH), heritable
ulmonary arterial hypertension (HPAH), and drugs and toxin
nduced; PH associated with diseases such as connective
issue disease (CTD), HIV infection, portal hypertension,
ongenital heart disease (CHD) and schistosomiasis are also
ncluded in Group 1. Group 1′ and Group 1′′ refer to pul-
onary veno-occlusive disease and/or pulmonary capillary
aemangiomatosis and persistent pulmonary hypertension
f the newborn, respectively. Group 2 PH includes PH due
o left heart disease (LHD). Group 3 refers to PH due to
ung diseases or hypoxia, such as chronic obstructive pul-
onary disease (COPD) or interstitial lung disease. Group
PH includes chronic thromboembolic pulmonary hyper-
ension (CTEPH) and other pulmonary artery obstructions.
roup 5 refers to PH with unclear and/or multifactorial
echanisms.
Group 1 (PAH) aetiologies, except schistosomiasis asso-
iated PAH, are considered rare diseases; IPAH being an
xclusion diagnosis, is the most studied form of PAH and
he model for clinical management of PAH forms which
re indicated for targeted therapy.3,4 Treatment of PH
nvolves both conventional, symptom-based therapy and
argeted therapy, which is indicated for specific PH aeti-
logies. Conventional treatment involves the use of digoxin
o improve right ventricular function, diuretics to reduce
eripheral oedema, supplemental oxygen, and in specific
ases anticoagulants.3 Calcium channel blockers (CCBs) can
e used to lower PAP, but their use is restricted to a small
ercentage of patients (3--5%) showing positive response
o acute pulmonary vasodilator (ARVT) challenge.5,6 Tar-
eted therapy includes the use of endothelin-1 receptor
ntagonists (ERA),7--9 phosphodiesterase-5 inhibitors (PDE-
I),10,11 soluble guanylate cyclase (sGC) stimulators,12,13
a
i
(
nd prostacyclin analogues or receptor agonists,14--19 sur-
ical treatment, like lung or heart-lung transplantation
s reserved to refractory cases of PAH; pulmonary angio-
lasty and pulmonary endarterectomy is reserved to CTEPH
atients.
The proliferation of studies assessing long-term prognosis
f PH has helped identify considerably different patients and
isease characteristics both over time and for populations in
ifferent geographical regions.20 These findings suggest the
eed for specific regional data, to fully characterise local
isease populations, inform clinical practice, and to help
efine local/regional political strategies.
In Portugal, a national PH registry has been, but given
ts recent implementation, only short-term data have been
ublished.21 Recently, another study characterised the sur-
ival over a longer follow-up period but the sample size
emained relatively small (n = 66).22
This study aims to provide long-term data for the
ortuguese PH population, by characterising the clinical
resentation, evolution, and outcomes of PH patients in a
pecialised referral centre in Portugal.
aterials and methods
tudy population
e conducted a retrospective analysis of a cohort of PH
atients referenced to an expert tertiary care referral cen-
re in northern Portugal (Pulmonary Vascular Disease Unit,
entro Hospitalar do Porto -- Hospital de Santo António,
orto, Portugal) from 2002 to 2013. At this centre, patients
ollowed a defined protocol for the clinical management of
H, which was adjusted to the applicable national23 and
nternational guidelines during the period of the study. The
rotocol specified mandatory clinical assessments, which
ere prospectively collected in dedicated PH software
eveloped by the centre (PAHTool
®
, Inovultus Lda, Santa
aria da Feira, Portugal).
PH was confirmed by right heart catheterisation (RHC),
ith a mean pulmonary artery pressure (mPAP) ≥25 mmHg;
ulmonary arterial wedge pressure (PAWP) ≤15 mmHg was
sed to define pre-capillary PH. For the purposes of thisccording to the consensus from the 5th World Symposium
n Nice, 2013. Patients with left heart disease (LHD)
Group 2 PH) were not included in this study, due to the
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PH: real-world data from a Portuguese expert referral centr
significantly different pathophysiology, treatment
approaches, and prognosis.
The study was approved by the ethics committee of Hos-
pital de Santo António, Porto, Portugal. All patients provided
their written informed consent prior to enrolment in the
study.
Medical care
Patients received standard medical care throughout the
period of the study. Treatment was prescribed by the
accompanying physician based on national and interna-
tional guidelines applicable at time of the study (as
defined in the protocol implemented at the centre) and
local treatment availability. Overall, all patients received
standard conventional treatment when clinically indicated,
including anticoagulants, diuretics, digoxin, oxygen supple-
mentation, and high dose calcium channel blockers (CCBs)
(if they were AVRT responders). Selected patients received
molecular targeted therapy in addition to conventional
therapy, including endothelin-1 receptor antagonists (ERA),
phosphodiesterase-5 inhibitors (PDE-5I), and prostacyclin
analogues.
Assessments
Demographic characteristics (gender and age) and clinical
characteristics (PH aetiology, symptoms, WHO functional
class, 6-min walking test (6MWT), N-terminal pro brain
natriuretic peptide (NT-proBNP), and haemodynamic param-
eters) were collected at baseline. According to the protocol
implemented at the centre, patients attended, routinely,
3--4 visits per year or if they had any sign of deterioration.
During follow-up the following assessments were considered
mandatory: type of treatment administered, clinical evalu-
ation focused on signs of deterioration (like heart failure
or syncope), WHO functional class, 6MWT, and NT-proBNP;
and yearly haemodynamic re-evaluation. Survival was estab-
lished based on the electronic medical records (EMR).
Statistical methods
Demographic and clinical variables were summarised with
descriptive statistics. Categorical variables were summ-
arised as absolute frequency and percentage, whereas
continuous variables were summarised as mean and standard
deviation (SD). Student’s t, Wilcoxon’s, Fisher’s exact, or
chi-square tests were used to conduct paired/independent
univariate/bivariate analysis as appropriate. Cumulative
survival was estimated using the Kaplan--Meier method.
Patients were censored at the end of the study, except for
those who underwent lung transplantation, censored at the
time of transplantation. Differences between the survival
curves (according to baseline characteristics and disease
aetiology) were analysed using the log-rank test. A 5% signif-
icance level was employed for all analyses. For the purpose
of subgroup analysis patients with multiple aetiology were
excluded from any subgroup analysis, except those for whom
CTEPH was considered their main diagnosis.
p
s
c
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Data was retrieved from PAHTool
®
. Statistical analysis
as conducted using IBM SPSS Statistics for Windows, Version
1.0 (IBM Corp., Armonk, NY, USA).
esults
tudy population and baseline characteristics
uring the enrolment period of the study, a total of 211
atients with suspected PH were referenced to the Pul-
onary Vascular Disease Unit (PDVU). RHC confirmed PH in
20 patients, of which, 19 were excluded from the analysis
10 patients lost to follow-up and 9 patients with exclusive
eft heart disease), leading to a final study cohort of 101
atients with pcPH. The majority of patients represented
ncident cases (n = 81, 80.2%), however, 20 (19.8%) patients
ad a prior diagnosis of congenital heart diseases before
eferral, having started specific therapy at admission to the
entre. Fig. 1 presents the patient disposition in the study
ohort.
The mean ± SD follow-up time in the overall study pop-
lation was 3.8 ± 2.7 years. Table 1 presents the baseline
emographic and clinical characteristics of the study pop-
lation. Approximately 66.3% of patients were female (3:1
atio) and the mean ± SD age at baseline was 49.6 ± 19.6
ears. Most participants showed moderate to severe disease
anifestations at baseline, with 60.4% of patients pre-
enting in WHO functional classes (FC) III or IV, with a mean
T-proBNP level of 1533.4 ± 1758.3 pg/mL, and walking a
ean distance of 319.6 ± 132.9 m on 6MWT. Haemodynami-
ally, patients showed increased mPAP of 48.5 ± 16.5 mmHg,
ncreased PVR of 8.1 ± 4.8 wood units, increased RAP
1.1 ± 5.3 mmHg, and normal CI of 3.0 ± 1.1 L/min.
The most frequent causes of PH were Group 1 PH -- PAH
54.4%) and Group 4 PH -- CTEPH (25.7%); from the PAH
ubgroup, CHD (36.3%) was the most frequent, followed
y I/HPAH (32.7%), and CTD (20.0%); importantly, 17.8% of
atients presented PH of multiple aetiology.
Concerning the most frequent PH subgroups, I/HPAH
nd CHD patients were younger (P < 0.001); for all sub-
roups of aetiologies most patients presented with WHO FC
II/IV, but patients with CHD and CTEPH showed significantly
P < 0.001) worst functional capacity at baseline.
reatment and clinical evolution
able 2 shows PH treatment used at the last follow-up visit.
ll patients received conventional treatment during the
eriod of the study, with 8.9% of those receiving conven-
ional therapy only. Targeted therapy was used with 91.1%
f participants in addition to conventional therapy. 4 (6.8%)
/HPAH patients were AVRT responders, but only 2 were long-
erm responders, being treated with high doses of CCBs only.
Single targeted therapy was used in 42.6% of patients,
ual combination therapy in 29.7%, and triple combina-
ion therapy in 18.8%. 42.3% of CTEPH patients underwent
ulmonary endarterectomy during the course of the
tudy. The majority of patients with I/HPAH were under
ombination therapy (88.9%), with 61.1% under triple ther-
py. Most patients with CTD (54.4%) and CHD (55.0%) were
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Patients referred for suspected PH, n=211
referred o pulmonary vascular disease unit from
April 2002 to October 2013
Total excluded, n=91
PH not confirmed, n=91
PH cases, n=120
confirmed by RHC
Total excluded, n=19
lost to follow-up, n=10
left heart disease, n=9
Study population, N=101
Known mixed aetiology, n=18
CTD-LHD, n=3
CTD-LHD-PH-lung, n=1
CTD-LHD-CTEPH, n=1
CTD-CTEPH, n=2
CTD-metabolic disorders, n=1
HiV-portal hypertension, n=1
HiV-CHD, n=1
CHD-portal hypertension, n=1
CHD-LHD, n=2
CHD-PH-lung, n=3
CTEPH-LHD, n=2
1.1 idiopathic PAH, n=16 3.3 Other pulmonary diseases
with mixed restrictive and
obstructive pattern, n=2
4. Chronic thromboembolic
pulmonary hypertension, n=21
5.1 Haematological disorders, n=1
5.2 Systemic disorders, n=3
5.4 Others, n=1
1.2 Heriatable PAH, n=2
1.4.1 Connective tissue
disease, n=11
1.4.2 HIV infection, n=3
1.4.3 Portal hypertension, n=3
1.4.4 Congenital heart
disease, n=20
Group 1 - PAH, n=55 Group 3 - PH-lung, n=2 Group 4 - CTEPH, n=21 Group 5 - PH-multi, n=5
Figure 1 The study cohort. PH: pulmonary hypertension; RHC: right heart catheterisation; PAH: pulmonary arterial hypertension;
PH-lung: pulmonary hypertension associated with lung disease; CTEPH: chronic thromboembolic pulmonary hypertension; PH-misc:
miscellaneous pulmonary hypertension.
Table 1 Baseline demographic and clinical characteristics.
Overall(n = 101) I/HPAH (n = 18) CTD (n = 11) CHD (n = 20) CTEPH (n = 26) P-value
Age, years 49.6 ± 19.6 36.4 ± 14.9 56.6 ± 4.7 35.3 ± 5.2 60.1 ± 14.0 <0.001
Female, n (%) 67 (66.3) 12 (66.7) 9 (81.8) 11 (55.0) 18 (69.2) 0.466
WHO FC, n (%)
I/II 40 (39.6) 9 (50.0) 6 (45.5) 6 (30.0) 8 (30.7) 0.220
III/IV 61 (60.4) 9 (50.0) 5 (54.5) 14 (70.0) 18 (69.3)
6MWT, m 319.6 ± 132.9 360.7 ± 117.5 297.3 ± 53.6 330.7 ± 24.1 289.4 ± 144.3 0.380
NT-proBNP, pg/mL 1533.4 ± 1758.3 1543.8 ± 1712.6 2081.9 ± 909.8 1139.3 ± 277.4 2163.8 ± 1805.5 0.349
Haemodynamics
mPAP, mmHg 48.5 ± 16.5 56.9 ± 17.7 38.3 ± 3.3 77.6 ± 7.8 44.6 ± 7.7 <0.001
PAWP, mmHg 11.1 ± 5.3 10.8 ± 5.2 7.6 ± 0.9 19.0 ± 2.1 9.79 ± 4.81 0.002
RAP, mmHg 8.2 ± 4.6 9.6 ± 5.2 4.6 ± 0.5 5.0 ± 1.0 8.9 ± 5.4 0.092
CO, L/min 5.2 ± 1.8 4.7 ± 1.7 5.3 ± 0.6 5.0 ± 1.2 4.73 ± 1.22 0.739
CI, L/min 3.0 ± 1.1 2.9 ± 1.2 3.0 ± 0.3 3.3 ± 0.4 2.72 ± 0.71 0.739
PVR, WU 8.1 ± 4.8 11.4 ± 6.7 6.1 ± 0.9 13.2 ± 3.4 7.87 ± 2.65 0.076
Results are presented as mean ± SD, except when otherwise indicated.
IPAH: idiopathic pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; CTD: connective tissue disease;
CHD: congenital heart disease; CTEPH: chronic thromboembolic pulmonary hypertension; WHO FC: World Health Organization functional
class; 6MWD: 6-min walk distance; NT-proBNP: N-terminal pro brain natriuretic peptide; mPAP: mean pulmonary artery pressure; PCWP:
pulmonary capillary wedge pressure; RAP: right atrial pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance.
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Table 2 Medical and surgical treatment at the last follow-up visit.
Treatment Overall(n = 101) I/HPAH(n = 18) CTD(n = 11) CHD(n = 20) CTEPH(n = 26)
Single targeted treatment
Patients under monotherapy only 43 (42.6) 3 (16.7) 4 (36.4) 9 (45.0) 15 (57.7)
PDE-5I 5 (5.0) 0 (0.0) 0 (0.0) 1 (5.0) 3 (11.5)
ERA 38 (37.6) 3 (16.7) 4 (36.4) 8 (40.0) 12 (46.2)
Combination treatment
Patients under combination therapy 49 (48.5) 16 (88.9) 6 (54.5) 11 (55.0) 11 (42.3)
Dual combination therapy 30 (29.7) 5 (27.8) 4 (36.4) 9 (45.0) 8 (30.8)
Triple combination therapy 19 (18.8) 11 (61.1) 2 (18.2) 2 (10.0) 3 (11.5)
PDE-5I + Prostanoids 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Prostanoids + ERA 9 (8.9) 2 (11.1) 1 (9.1) 1 (5.0) 4 (15.4)
PDE-5I + ERA 21 (20.8) 3 (16.7) 3 (27.3) 8 (40.0) 4 (15.4)
PDE-5I + Prostanoids + ERA 19 (18.8) 11 (61.1) 2 (18.2) 2 (10.0) 3 (11.5)
Surgical treatment
Pulmonary endarterectomy 11 (10.9) NA NA NA 11 (42.3)
Conventional treatment
Conventional therapy only 9 (8.9) 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0)
Conventional plus targeted therapy 92 (91.1) 18 (100.0) 10 (90.9) 20 (100.0) 26 (100.0)
Results are presented as absolute frequency (percentage).
IPAH: idiopathic pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; CTD: connective tissue disease;
CHD: congenital heart disease; CTEPH: chronic thromboembolic pulmonary hypertension; PDE-5I: phosphodiesterase-5 inhibitors; ERA:
endothelin-1 receptor antagonists; NA: not applicable.
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Figure 2 Change in functional capacity,
under combination therapy, and dual therapy was the most
frequent type of treatment (36.4% and 45.0%, respec-
tively). Patients with non-operable CTEPH or with residual
persistent PH were mostly under monotherapy (57.7%), par-
ticularly with ERAs (46.2%).
During patient follow-up, functional capacity improved
significantly (P < 0.003) from first to last visit for the overall
study population, as illustrated in Fig. 2. Mean 6MWD signif-
icantly improved in the overall population (P = 0.003) and in
u
(
C
sured by WHO FC, from first do last visit.
he subgroup of I/HPAH patients (P = 0.011). CHD subgroup
as the only one to show a significant (P = 0.040) improve-
ent in NT-proBNP levels (Table 3).
There was a significant reduction in mPAP in the overall
opulation (P = 0.002) and in the subgroup of I/HPAH patients
P = 0.008). PVR significantly improved in the overall pop-
lation (P = 0.008) and in the subgroup of I/HPAH patients
P = 0.008). No significant changes were observed in RAP and
I for either the overall population or subgroup analyses.
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Table 3 6MWD and NT-proBNP evolution from first to last visit.
Overall (n = 101) I/HPAH
(n = 18)
CTD
(n = 11)
CHD
(n = 20)
CTEPH
(n = 26)
First visit Last visit First visit Last visit First visit Last visit First visit Last visit First visit Last visit
6MWD, m 319.6 ± 132.9 357.7 ± 162.1** 360.7 ± 117.5 463.3 ± 163.1 297.3 ± 53.6 282.5 ± 163.8 330.7 ± 24.1 319.8 ± 164.8 289.4 ± 144 337.2 ± 156.2
NT-proBNP,
pg/mL
1533.4 ± 1758.3 1963.9 ± 3627.2 1543.8 ± 1712.5 1583.2 ± 3761.9 2081.9 ± 909.8 3392.8 ± 3732.1 1139.3 ± 277.4 1815.9 ± 3671.7* 2163.8 ± 1805.5 2960.1 ± 5098.3
Results are presented as mean ± SD.
6MWD: 6-min walk distance; NT-proBNP: N-terminal pro brain natriuretic peptide.
* <0.05.
** <0.01.
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Table 4 Kaplan--Meier survival estimates.
Cumulative probability
of survival, %
Total cohort (n = 101)
1 year from diagnosis 86.6
3 years from diagnosis 76.7
5 years from diagnosis 64.1
Group 1 PH -- PAH (n = 55)
1 year from diagnosis 91.8
3 years from diagnosis 80.3
5 years from diagnosis 66.2
Group 4 PH -- CTEPH (n = 26)
1 year from diagnosis 81.5
3 years from diagnosis 75.3
5 years from diagnosis 67.3
PH: pulmonary hypertension; PAH: pulmonary arterial hyperten-
sion; CTEPH: chronic thromboembolic pulmonary hypertension.
Survival estimates for subgroups of PH were not calculated due
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Figure 4 Kaplan--Meier survival curves for subgroups of
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to limitations introduced by reduced sample size and variable
follow-up times in the subgroups.
Survival
During the follow-up period, a total of 28 (27.7%) patients
died of PH-related causes; 10.7% of deaths occurred in
patients with I/HPAH, 25.0% with CTEPH, 10.7% with CTD,
and 25.0% with CHD. Patients with WHO FC III or IV at base-
line represented 67.9% of deaths. Median survival time from
diagnosis by RHC for the 28 deaths was 3.1 years. At the time
of death 35.7% of patients were under monotherapy, 39.3%
under dual therapy, 17.9% under triple therapy, and only 2
patients (7.1%) were under exclusive conventional therapy.
Table 4 presents survival estimates for the overall
study cohort and specific PH aetiologies. For the overall
study cohort, 1-, 3-, and 5-year survival was estimated at
86.6%, 76.7%, and 64.1%, respectively. Fig. 3 shows the
Kaplan--Meier survival curve for the overall cohort and
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Figure 3 Kaplan--Meier survival curve for the overall study
cohort, patients with PAH (Group 1 PH) and patients with CTEPH
(Group 4 PH).
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ent.
or patients with PAH vs. CTEPH. Fig. 4 shows specific
aplan--Meier survival curves for subgroups of PAH (A) and
ccording to CTEPH treatment (B).
Survival was significantly better for those ≤40 years old
10.5 vs. 6.4 years; P = 0.003) and in women with I/HPAH
ompared with men (9.3 vs. 4.5 years; P = 0.039); no other
ignificant differences in survival were observed for gender,
ge, PH aetiology, and functional capacity analyses for the
verall population and subgroups of aetiologies.
iscussion
his study provides long-term data for patient phenotypes,
linical evolution, and survival in PAH and CTEPH of a Por-
uguese PH population. These results build on previous
ndings21,24 and together they characterise the impact of
his life-threatening disease in Portugal. The present study
nrolled only patients with pcPH due to the substantially
ifferent disease characteristics and treatment approaches
hat could bias the results and ultimately hinder compar-
sons with other cohorts published over the years. Unlike
revious studies, here we included patients with all types
f PH, except for left heart disease, to provide a more
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ccurate picture of pcPH as a whole. Left heart disease was
he only PH group excluded from the analysis.
The PH dedicated software developed by the centre
llowed the implementation of a mandatory case report
orm (CRF) with automatic alerts to avoid missing data in
ur clinical records. This methodology allowed us to build a
rue real-world cohort of PH patients from our region and
ollowing the most recent Nice recommendations.25 This is
articularly relevant because PAHTool
®
is currently licenced
or implementation in several PH centres worldwide, and its
idespread use is envisioned to allow the generation of rel-
vant real-world data, which is badly needed in the context
f this non-frequent condition but rapidly evolving field.
According to existing registries, some aetiologies are
nderrepresented in our cohort (particularly drugs and tox-
ns induced PH, HIV and portal hypertension associated PH),
hich is most likely due to low physician awareness about
H.21,26--36 CHD (36.3% of PAH group) contributed with a
omparatively higher proportion of cases, which can be
xplained by the past low levels of detection and correc-
ion of heart defects in infancy in our country and by the
act that our centre was for a long time the only one to
rovide targeted therapy for PAH in the region. CTEPH was
he most frequent aetiology after PAH, confirming the high
revalence of this frequently forgotten condition and in line
ith studies that included this subgroup of patients.21,34,37--39
Comparing our data with the most important registries in
he field, we found that CTEPH age at diagnosis in our pop-
lation is consistent with these registries38--40; although the
ean age at diagnosis for our overall population is similar to
he majority of PAH registries26,29,32 the mean age for I/HPAH
s clearly lower and near the pioneer registries35,41 and those
oming from the developing world,42,43 but still in line with
ational data.21 Female gender (66%) predominance is also
n line with the majority of PH registries and cohorts.21,26--35
Baseline clinical characteristics at presentation indicate
ome delay in diagnosis, with most patients presenting with
ntermediate or high risk of mortality indicated by high NYHA
C, low 6MWD and high NT-proBNP according to risk assess-
ent guidelines3; increased RAP (11.1 ± 5.3 mmHg) and PVR
8.1 ± 4.8 WU) are also consistent with these findings. The
roportion of patients presenting with intermediate or high
isk explains why the great majority of patients were treated
ith combination therapy: I/HPAH (88.9%), CTD (54.5%) and
HD (55.0%). These findings are, however, above what has
een reported in recent European studies, as well as national
ata.21,30,32,34,44 There is a particularly high proportion of
/HPAH (61.1%) patients under triple therapy, which is proba-
ly the result of the close follow-up adopted and continuous
isk evaluation with early step up of the therapy. ERAs and
DE-5I were the most widely used drugs, which is in accor-
ance with previous reports.21,30,32,34,44 Still, they were used
ar more frequently in combination than what has been
eported, which is in line with the most recent recommen-
ations for the early use of sequential or upfront double
ombination therapy.3,45
Although pulmonary endarterectomy surgery is not
outinely available in our country, patients are fully reim-
ursed by the Portuguese Public National Health Service
f surgery is performed abroad. Despite limitations associ-
ted with the need for a cross-border, high risk procedure,
2% of CTEPH patients had the operation in a foreign
A
T
p
A. Gomes et al.
entre, thanks to a protocol for surgical treatment of PH
stablished in 2000. Non-operable patients, patients refus-
ng pulmonary endarterectomy, or patients with residual
ersistent PH after pulmonary endarterectomy were pre-
ominantly treated with monotherapy (57.7%) and specially
ith ERAs (46.2%), as per previous studies.39,40
In terms of clinical outcomes during the period of the
tudy, WHO FC, 6MWD, mPAP and PVR significantly improved
or the overall population, which is in line with the accumu-
ating evidence of substantial gains in long-term prognosis
btained over recent decades, following the introduction of
everal therapeutic alternatives.3,30,32,34
Although usual bias for survival estimates were elim-
nated in this study (including mixed population of
ncident/prevalent cases and ‘‘immortal’’ bias), survival
stimates should still be considered with caution since there
ere substantial changes in treatment strategies during the
ourse of the study. Nonetheless, survival estimates found
or the total cohort and PAH follow the trends of the most
elevant international registries26--28,30,32,35; the 1-year sur-
ival among CTEPH patients (81.5%) was considerably below
stimates from other studies (88--97%),37--40 which could be
onnected to difficulties of access to PEA surgery.
This study had several limitations. First, its single-centre
ature might affect the representativeness of the findings
or the overall Portuguese population, however, the study
as conducted at one of the largest PH centres in the coun-
ry, serving the northern region, with an ample and diverse
roup of patients currently being followed. Second, the rela-
ively small sample size impaired the ability to perform more
n-depth statistical analysis such as predictors of survival,
owever, in the context of a non-frequent disease the data
rovided by this study gives highly relevant insight to inform
linical practice. Third, the enrolment period for this study
as long, which is associated with highly variable follow-up
imes and variable treatment approaches over time. Still,
he low incidence of PH and the country/region dimension
ake enrolment over reduced periods difficult.
onclusions
his study provides long-term, real-world data for the
anagement of PH in Portugal. It also demonstrates the
otential of a dedicated information system for PAH in gen-
rating high-quality real-world data aimed at characterising
H in present clinical practice conditions. Patients pre-
ented mostly with intermediate or high risk of mortality
hich might be indicative of delay in diagnosis and high-
ights the need to increase awareness and early referral to
xpert centres for this condition among clinicians.
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